Treating juvenile idiopathic arthritis to target

recommendations of an international task force

Angelo Ravelli, Alessandro Consolaro, Gerd Horneff, Ronald M Laxer, Daniel J Lovell, Nico M Wulffraat, Jonathan D Akikusa, Sulaiman M Al-Mayouf, Jordi Antón, Tadej Avcin, Roberta A Berard, Michael W Beresford, Ruben Burgos-Vargas, Rolando Cimaz, Fabrizio De Benedetti, Erkan Demirkaya, Dirk Foell, Yasuhiko Itoh, Pekka Lahdenne, Esi M Morgan & 11 others Pierre Quartier, Nicolino Ruperto, Ricardo Russo, Claudia Saad-Magalhães, Sujata Sawhney, Christiaan Scott, Susan Shenoi, Joost F Swart, Yosef Uziel, Sebastiaan J Vastert, Josef S Smolen

Research output: Contribution to journalArticle

Abstract

Recent therapeutic advances in juvenile idiopathic arthritis (JIA) have made remission an achievable goal for most patients. Reaching this target leads to improved outcomes. The objective was to develop recommendations for treating JIA to target. A Steering Committee formulated a set of recommendations based on evidence derived from a systematic literature review. These were subsequently discussed, amended and voted on by an international Task Force of 30 paediatric rheumatologists in a consensus-based, Delphi-like procedure. Although the literature review did not reveal trials that compared a treat-to-target approach with another or no strategy, it provided indirect evidence regarding an optimised approach to therapy that facilitated development of recommendations. The group agreed on six overarching principles and eight recommendations. The main treatment target, which should be based on a shared decision with parents/patients, was defined as remission, with the alternative target of low disease activity. The frequency and timeline of follow-up evaluations to ensure achievement and maintenance of the target depend on JIA category and level of disease activity. Additional recommendations emphasise the importance of ensuring adequate growth and development and avoiding long-term systemic glucocorticoid administration to maintain the target. All items were agreed on by more than 80% of the members of the Task Force. A research agenda was formulated. The Task Force developed recommendations for treating JIA to target, being aware that the evidence is not strong and needs to be expanded by future research. These recommendations can inform various stakeholders about strategies to reach optimal outcomes for JIA.

Original languageEnglish
Pages (from-to)819-828
Number of pages10
JournalAnnals of the Rheumatic Diseases
Volume77
Issue number6
DOIs
Publication statusPublished - Jun 2018

Fingerprint

Juvenile Arthritis
Advisory Committees
Pediatrics
Glucocorticoids
Growth and Development
Consensus
Therapeutics
Parents
Maintenance
Research
TimeLine

Cite this

Treating juvenile idiopathic arthritis to target : recommendations of an international task force. / Ravelli, Angelo; Consolaro, Alessandro; Horneff, Gerd; Laxer, Ronald M; Lovell, Daniel J; Wulffraat, Nico M; Akikusa, Jonathan D; Al-Mayouf, Sulaiman M; Antón, Jordi; Avcin, Tadej; Berard, Roberta A; Beresford, Michael W; Burgos-Vargas, Ruben; Cimaz, Rolando; De Benedetti, Fabrizio; Demirkaya, Erkan; Foell, Dirk; Itoh, Yasuhiko; Lahdenne, Pekka; Morgan, Esi M; Quartier, Pierre; Ruperto, Nicolino; Russo, Ricardo; Saad-Magalhães, Claudia; Sawhney, Sujata; Scott, Christiaan; Shenoi, Susan; Swart, Joost F; Uziel, Yosef; Vastert, Sebastiaan J; Smolen, Josef S.

In: Annals of the Rheumatic Diseases, Vol. 77, No. 6, 06.2018, p. 819-828.

Research output: Contribution to journalArticle

Ravelli, A, Consolaro, A, Horneff, G, Laxer, RM, Lovell, DJ, Wulffraat, NM, Akikusa, JD, Al-Mayouf, SM, Antón, J, Avcin, T, Berard, RA, Beresford, MW, Burgos-Vargas, R, Cimaz, R, De Benedetti, F, Demirkaya, E, Foell, D, Itoh, Y, Lahdenne, P, Morgan, EM, Quartier, P, Ruperto, N, Russo, R, Saad-Magalhães, C, Sawhney, S, Scott, C, Shenoi, S, Swart, JF, Uziel, Y, Vastert, SJ & Smolen, JS 2018, 'Treating juvenile idiopathic arthritis to target: recommendations of an international task force', Annals of the Rheumatic Diseases, vol. 77, no. 6, pp. 819-828. https://doi.org/10.1136/annrheumdis-2018-213030
Ravelli, Angelo ; Consolaro, Alessandro ; Horneff, Gerd ; Laxer, Ronald M ; Lovell, Daniel J ; Wulffraat, Nico M ; Akikusa, Jonathan D ; Al-Mayouf, Sulaiman M ; Antón, Jordi ; Avcin, Tadej ; Berard, Roberta A ; Beresford, Michael W ; Burgos-Vargas, Ruben ; Cimaz, Rolando ; De Benedetti, Fabrizio ; Demirkaya, Erkan ; Foell, Dirk ; Itoh, Yasuhiko ; Lahdenne, Pekka ; Morgan, Esi M ; Quartier, Pierre ; Ruperto, Nicolino ; Russo, Ricardo ; Saad-Magalhães, Claudia ; Sawhney, Sujata ; Scott, Christiaan ; Shenoi, Susan ; Swart, Joost F ; Uziel, Yosef ; Vastert, Sebastiaan J ; Smolen, Josef S. / Treating juvenile idiopathic arthritis to target : recommendations of an international task force. In: Annals of the Rheumatic Diseases. 2018 ; Vol. 77, No. 6. pp. 819-828.
@article{74916add76674383af60ad3ce9d9405f,
title = "Treating juvenile idiopathic arthritis to target: recommendations of an international task force",
abstract = "Recent therapeutic advances in juvenile idiopathic arthritis (JIA) have made remission an achievable goal for most patients. Reaching this target leads to improved outcomes. The objective was to develop recommendations for treating JIA to target. A Steering Committee formulated a set of recommendations based on evidence derived from a systematic literature review. These were subsequently discussed, amended and voted on by an international Task Force of 30 paediatric rheumatologists in a consensus-based, Delphi-like procedure. Although the literature review did not reveal trials that compared a treat-to-target approach with another or no strategy, it provided indirect evidence regarding an optimised approach to therapy that facilitated development of recommendations. The group agreed on six overarching principles and eight recommendations. The main treatment target, which should be based on a shared decision with parents/patients, was defined as remission, with the alternative target of low disease activity. The frequency and timeline of follow-up evaluations to ensure achievement and maintenance of the target depend on JIA category and level of disease activity. Additional recommendations emphasise the importance of ensuring adequate growth and development and avoiding long-term systemic glucocorticoid administration to maintain the target. All items were agreed on by more than 80{\%} of the members of the Task Force. A research agenda was formulated. The Task Force developed recommendations for treating JIA to target, being aware that the evidence is not strong and needs to be expanded by future research. These recommendations can inform various stakeholders about strategies to reach optimal outcomes for JIA.",
author = "Angelo Ravelli and Alessandro Consolaro and Gerd Horneff and Laxer, {Ronald M} and Lovell, {Daniel J} and Wulffraat, {Nico M} and Akikusa, {Jonathan D} and Al-Mayouf, {Sulaiman M} and Jordi Ant{\'o}n and Tadej Avcin and Berard, {Roberta A} and Beresford, {Michael W} and Ruben Burgos-Vargas and Rolando Cimaz and {De Benedetti}, Fabrizio and Erkan Demirkaya and Dirk Foell and Yasuhiko Itoh and Pekka Lahdenne and Morgan, {Esi M} and Pierre Quartier and Nicolino Ruperto and Ricardo Russo and Claudia Saad-Magalh{\~a}es and Sujata Sawhney and Christiaan Scott and Susan Shenoi and Swart, {Joost F} and Yosef Uziel and Vastert, {Sebastiaan J} and Smolen, {Josef S}",
note = "{\circledC} Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.",
year = "2018",
month = "6",
doi = "10.1136/annrheumdis-2018-213030",
language = "English",
volume = "77",
pages = "819--828",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "6",

}

TY - JOUR

T1 - Treating juvenile idiopathic arthritis to target

T2 - recommendations of an international task force

AU - Ravelli, Angelo

AU - Consolaro, Alessandro

AU - Horneff, Gerd

AU - Laxer, Ronald M

AU - Lovell, Daniel J

AU - Wulffraat, Nico M

AU - Akikusa, Jonathan D

AU - Al-Mayouf, Sulaiman M

AU - Antón, Jordi

AU - Avcin, Tadej

AU - Berard, Roberta A

AU - Beresford, Michael W

AU - Burgos-Vargas, Ruben

AU - Cimaz, Rolando

AU - De Benedetti, Fabrizio

AU - Demirkaya, Erkan

AU - Foell, Dirk

AU - Itoh, Yasuhiko

AU - Lahdenne, Pekka

AU - Morgan, Esi M

AU - Quartier, Pierre

AU - Ruperto, Nicolino

AU - Russo, Ricardo

AU - Saad-Magalhães, Claudia

AU - Sawhney, Sujata

AU - Scott, Christiaan

AU - Shenoi, Susan

AU - Swart, Joost F

AU - Uziel, Yosef

AU - Vastert, Sebastiaan J

AU - Smolen, Josef S

N1 - © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

PY - 2018/6

Y1 - 2018/6

N2 - Recent therapeutic advances in juvenile idiopathic arthritis (JIA) have made remission an achievable goal for most patients. Reaching this target leads to improved outcomes. The objective was to develop recommendations for treating JIA to target. A Steering Committee formulated a set of recommendations based on evidence derived from a systematic literature review. These were subsequently discussed, amended and voted on by an international Task Force of 30 paediatric rheumatologists in a consensus-based, Delphi-like procedure. Although the literature review did not reveal trials that compared a treat-to-target approach with another or no strategy, it provided indirect evidence regarding an optimised approach to therapy that facilitated development of recommendations. The group agreed on six overarching principles and eight recommendations. The main treatment target, which should be based on a shared decision with parents/patients, was defined as remission, with the alternative target of low disease activity. The frequency and timeline of follow-up evaluations to ensure achievement and maintenance of the target depend on JIA category and level of disease activity. Additional recommendations emphasise the importance of ensuring adequate growth and development and avoiding long-term systemic glucocorticoid administration to maintain the target. All items were agreed on by more than 80% of the members of the Task Force. A research agenda was formulated. The Task Force developed recommendations for treating JIA to target, being aware that the evidence is not strong and needs to be expanded by future research. These recommendations can inform various stakeholders about strategies to reach optimal outcomes for JIA.

AB - Recent therapeutic advances in juvenile idiopathic arthritis (JIA) have made remission an achievable goal for most patients. Reaching this target leads to improved outcomes. The objective was to develop recommendations for treating JIA to target. A Steering Committee formulated a set of recommendations based on evidence derived from a systematic literature review. These were subsequently discussed, amended and voted on by an international Task Force of 30 paediatric rheumatologists in a consensus-based, Delphi-like procedure. Although the literature review did not reveal trials that compared a treat-to-target approach with another or no strategy, it provided indirect evidence regarding an optimised approach to therapy that facilitated development of recommendations. The group agreed on six overarching principles and eight recommendations. The main treatment target, which should be based on a shared decision with parents/patients, was defined as remission, with the alternative target of low disease activity. The frequency and timeline of follow-up evaluations to ensure achievement and maintenance of the target depend on JIA category and level of disease activity. Additional recommendations emphasise the importance of ensuring adequate growth and development and avoiding long-term systemic glucocorticoid administration to maintain the target. All items were agreed on by more than 80% of the members of the Task Force. A research agenda was formulated. The Task Force developed recommendations for treating JIA to target, being aware that the evidence is not strong and needs to be expanded by future research. These recommendations can inform various stakeholders about strategies to reach optimal outcomes for JIA.

U2 - 10.1136/annrheumdis-2018-213030

DO - 10.1136/annrheumdis-2018-213030

M3 - Article

VL - 77

SP - 819

EP - 828

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 6

ER -